Lundbeck's quarterly report is being released on Tuesday, and is expected to account for three months dominated by setbacks.
The patents for several drugs have expired, and lockdowns and infection risks are predicted to have reduced the number of patients that have started using Lundbeck's key products.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.